Reactive surgical implant

• US 8,241,654 B2
• Filed: 08/27/2009
• Issued: 08/14/2012
• Est. Priority Date: 09/26/2008
• Status: Active Grant

• Current Assignee: Covidien LP (Medtronic Plc)
• Original Assignee: Tyco Healthcare Group LP (Medtronic Plc)
• Inventors: Stopek, Joshua B.
• Primary Examiner(s): Kwon, Brian-Yong S
• Assistant Examiner(s): BECKHARDT, LYNDSEY MARIE
• Application Number:
  US12/548,524
• Publication Number:
  US 20100080838A1
• Time in Patent Office: 1,083 Days
• Field of Search: None
• US Class Current: 424/423
• CPC Class Codes: A61L 15/42 Use of materials characterised by their function or physical properties liquid bandages A61L26/00
• CPC Class Codes: A61L 31/14 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61P 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Abstract

Biocompatible implants including a polymer substrate and a reactive component for implant fixation in situ. The reactive component in combination with the substrate creates a reactive implant which bonds to a tissue surface in situ.

Claims

1. A medical device comprising:

a substrate in combination with a reactive component having at least one free reactive group, wherein the combination of the substrate and the reactive component create a reactive implant for chemically bonding the reactive implant with a tissue surface upon implantation, wherein the reactive component is present on the reactive implant in an amount of from about 0.05% by weight of the reactive implant to about 5% by weight of the reactive implant and wherein the reactive component is genipin.

2. The medical device of claim 1, wherein the substrate comprises a material selected from the group consisting of gelatin, collagen, fibrin, fibrinogen, elastin, keratin, albumin, hydroxyethyl cellulose, cellulose, oxidized cellulose, hydroxypropyl cellulose, carboxyethyl cellulose, carboxymethyl cellulose, trimethylene carbonate, caprolactone, dioxanone, glycolic acid, lactic acid, glycolide, lactide, polytetrafluoroethylenes, polyethylene terephthalate, polyurethanes, and combinations thereof.

3. The medical device of claim 1, wherein the reactive component contacts the substrate in situ.

4. The medical device of claim 1, wherein the reactive component is coated on at least a portion of a surface of the substrate.

5. The medical device of claim 1, wherein the substrate and the reactive component are contacted in situ.

6. The medical device of claim 1, wherein the reactive component comprises a solution at a concentration of from about 0.1% w/v to about 10% w/v.

7. The medical device of claim 1, wherein the substrate is selected from the group consisting of sutures, staples, stents, meshes, tapes, gauzes, soft tissue repair devices, buttresses, bands, ribbons, grafts, scaffolds, wound dressings, and foams.

8. The medical device of claim 7, wherein the medical device is a mesh.

9. The medical device of claim 1, wherein the medical device further comprises a polymer coating.

10. The medical device of claim 1, wherein the medical device further comprises a bioactive agent.

11. A reactive implant comprising a porous substrate in combination with a reactive component, wherein the reactive component includes a first reactive group that chemically bonds the reactive component to the porous substrate and a second reactive group that crosslinks the porous substrate to at least one tissue surface, wherein the reactive component is present on the reactive implant in an amount of from about 0.001% by weight of the reactive implant to about 10% by weight of the reactive implant, and wherein the reactive component is genipin.